共 50 条
- [41] Incorporating risk preferences of patients in the valuation of immune checkpoint inhibitors for non-small cell lung cancer FRONTIERS IN ONCOLOGY, 2023, 13
- [42] Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4503 - 4518
- [46] Outcomes of immune checkpoint inhibitors for postoperative recurrence of non-small cell lung cancer General Thoracic and Cardiovascular Surgery, 2023, 71 : 534 - 541
- [48] Neoadjuvant Therapy with Immune Checkpoint Inhibitors in operable non-small cell Lung Cancer CHIRURG, 2021, 92 (08): : 735 - 735
- [49] Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (01): : 50 - 59
- [50] Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer FRONTIERS IN IMMUNOLOGY, 2023, 14